News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ecopia BioSciences Inc. (EIA.TO) To Present At The EORTC-NCI-AACR Meeting In Prague



11/9/2006 10:53:54 AM

MONTREAL, QUEBEC -- (MARKET WIRE) -- November 08, 2006 -- Ecopia BioSciences Inc. (TSX: EIA) is pleased to announce it will present two scientific posters at the 18th EORTC-NCI-AACR Meeting, held in Prague. The data presented support the unique mechanism of action of ECO-4601 as well as its strong safety profile. ECO-4601, the Company's lead anticancer drug candidate now in a Phase I clinical trial, has a dual mechanism of action. Not only does the compound inhibit the RAS-mitogen-activated protein kinase (MAPK) pathway at a strategic point, it also selectively binds to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in many cancer cells. This dual activity positions the compound as a uniquely targeted anticancer drug candidate that is now being tested in a Phase I clinical trial involving patients with refractory solid tumors, including pancreatic cancer and glioblastoma.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES